Drugs / IMM01-STEM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06600581 | Dec 2024 → Jul 2026 overdue | — | Immunis, Inc. | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06784297 | — | muscular atrophy, obesity disorder | Immunis, Inc. | Temporarily not available | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05211986 Comparator | Sep 2022 → Mar 2026 overdue | muscular atrophy | Immunis, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMM01-STEM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05211986 ↗ |
| Route | Intramuscular | “twice weekly intramuscular administration of IMM01-STEM” NCT05211986 ↗ |